Isabel C Arrillaga-Romany MD

Neurooncology

Associate Clinical Director, Neuro-Oncology, MGH Cancer Center.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2009 - 2012
Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 2008 - 2009
Tufts University School of MedicineClass of 2008
Cornell UniversityB.A., Psychology, 1999

CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2015-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2015-2017

PubMed

Approved Targeted Treatments for Pediatric Brain Tumors.
Eric Bouffet, David Neal Franz, Isabel Arrillaga-Romany, Rakesh Jalali
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2026-06-01
Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step?
Mustafa Khasraw, Matthew D Dun, Isabel Arrillaga-Romany, Roel G W Verhaak, Eric Bouffet
Neuro-Oncology. 2026-05-22
1 citations
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
Tulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, Eudocia Q Lee, Isabel Arrillaga-Romany
Journal of Clinical Oncology. 2026-05-22

Journal Articles

Antiangiogenic Therapies for Glioblastoma
Arrillaga-Romany I, Norden A, CNS Oncology, 1/1/2014
Neurologic complications of cancer drug therapies
Lee EQ, Arrillaga-Romany I, Wen PY, Continuum (Minneapolis Minn), 1/1/2012

Books/Book Chapters

Controversies in Neuro-Oncology: Best Evidence Medicine for Brain Tumor Surgery.
Chapter: The Role of Adjuvant Therapy in Newly Diagnosed High Grade Astrocytoma.
Arrillaga-Romany I, Ahluwalia, MS, Wen PYEditors: Quinones-Hinojosa A, Raza SM.Thieme, New York, NY2014
Neuro-oncology
Chapter: Diagnosis of Brain Tumors: Clinical and Radiographic
Arrillaga-Romany I, Lee EQ and Wen PYEditors: R. J. Packer and D. Schiff.Blackwell Publishing Ltd., Oxford, United KingdomEdition 1st,2012

Abstracts/Posters

Newly Diagnosed Single Brain Mass - Implementation and performance of a hospital-wide management pathway.
Isabel Arrillaga-Romany, Aneesh Singhal, Susann Jarhult, Corey Gill3, Aurelie Cordier, Benjamin White2, SooAe Jones, Michelle Pisapia, Daniel Cahill, William Curry, Jo..., Neurology; Annual Meeting of American Academy of Neurology, Washington, DC, 1/1/2015
Structural Brain Changes in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma.
Isabel Arrillaga-Romany, Kourosh Jafari-Khouzani, Yi-Bin Chen, Bruce Rosen, Tracy Batchelor, and Jorg Dietrich, Neurology; Annual Meeting of American Academy of Neurology, Washington, DC, 1/1/2015
Eribulin induced neuropathy in a patient with previously undiagnosed Charcot-Marie-Tooth (CMT) disease.
Arrillaga-Romany I, Ruddy KJ, Greenberg SA, Nayak L, Society for Neuro-Oncology, San Francisco, CA, 1/21/2013

Lectures

Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.
2019 ASCO Annual Meeting - 6/1/2019
What's on the Horizon for Newly Diagnosed Glioblastoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Update on Central Nervous System Tumors
Harvard Medical School, Boston, MA - 1/1/2014

Other

The Pharmacology of Corticotropin-releasing Factor (CRF): Effects on Sensorimotor Gating in the Rat. (Thesis)
Arrillaga-Romany, I, Boston: ProQuest
1/1/2006

Chimerix (CMRX) Announces Positive ONC201 Data in Recurrent H3 K27M-Mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual MeetingNovember 19th, 2021
Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-Mutant GliomaNovember 4th, 2021
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma PublishedDecember 10th, 2019